372 related articles for article (PubMed ID: 32466202)
1. NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.
Zito Marino F; Pagliuca F; Ronchi A; Cozzolino I; Montella M; Berretta M; Errico ME; Donofrio V; Bianco R; Franco R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466202
[TBL] [Abstract][Full Text] [Related]
2. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
3. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
[TBL] [Abstract][Full Text] [Related]
4. NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
Kirchner M; Glade J; Lehmann U; Merkelbach-Bruse S; Hummel M; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Ploeger C; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A; Pfarr N
Genes Chromosomes Cancer; 2020 Aug; 59(8):445-453. PubMed ID: 32319699
[TBL] [Abstract][Full Text] [Related]
5. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
6. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.
Zito Marino F; Buono S; Montella M; Giannatiempo R; Messina F; Casaretta G; Arpino G; Vita G; Fiorentino F; Insabato L; Sgambato A; Orditura M; Franco R; Accardo M
J Pathol Clin Res; 2023 Sep; 9(5):367-377. PubMed ID: 37143440
[TBL] [Abstract][Full Text] [Related]
7. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
[TBL] [Abstract][Full Text] [Related]
9. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
[TBL] [Abstract][Full Text] [Related]
10. Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer.
Wong D; Yip S; Sorensen PH
Pathol Oncol Res; 2020 Jul; 26(3):1385-1399. PubMed ID: 31256325
[TBL] [Abstract][Full Text] [Related]
11. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
12. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
13. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
[TBL] [Abstract][Full Text] [Related]
14. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
15. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract][Full Text] [Related]
16. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
[TBL] [Abstract][Full Text] [Related]
17. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
[TBL] [Abstract][Full Text] [Related]
18. GISTs with
Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
[TBL] [Abstract][Full Text] [Related]
19. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
20. Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice.
Büchler T; Dundr P; Fínek J; Kiss I; Matěj R; Melichar B; Michal M; Petruželka L
Klin Onkol; 2020; 33(6):414-419. PubMed ID: 33685189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]